India’s health ministry issues new guidance telling states not to offer stem cell therapies as routine or commercial treatment, including for autism. The directive instructs that such interventions should not be marketed or provided as standard care when evidence of safety and effectiveness is not established.
The order applies to how clinics and providers present these therapies to patients, aiming to prevent routine use and sales of unproven treatments. It also emphasizes compliance with existing regulatory frameworks governing stem cell research and clinical use. Outlets report that providers are expected to follow the framework strictly, with penalties for non-compliance.
While coverage is aligned on the core measure—restricting stem cell therapy from being used as routine autism care—the reporting frames it slightly differently. One outlet highlights the ministry’s move to tighten rules broadly, while another focuses on autism specifically and the goal of stopping clinics from selling such treatments to families as though they were established therapy.
